TNFRSF4 and neoplasm: The authors performed pre-clinical studies comparing the anti-tumor efficacy of single-agent PD-L1, an agonistic OX40 antibody co-delivered with CpG DNA, and the combination of PD-L1 and OX40/CpG DNA (henceforth referred to as PDOX).